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Introduction
There are approximately 170,000 cases of Triple-Negative Breast Cancer (TNBC)
in the United States. TNBC treatment is inefficient due to infrequent response to
immunotherapies, and because of its resistance to common cancer chemotherapies.
The nucleosome remodeling factor (NURF) is a chromatin remodeling complex
composed of 3 core subunits with the BPTF being essential for function. BPTF is
commonly over-expressed in cancers and has shown to be associated with
increasing tumor growth and developing a malignant phenotype. These functions
suggest that NURF may act as a suppressor for the anti-tumor immune response.
Furthermore, in response to chemotherapies cancer cells often undergo the process
of Autophagy. In this process, cells consume their cellular components to conserve
energy and repair damage. Autophagy is regulated by many different proteins with
one of them being ATG5. ATG5 is a protein that is involved in the extension of the
isolation membrane into an autophagosome.
• Aim 1: Determine if BPTF-KD TNBCs are sensitive to chemotherapies. It is
expected that cells with BPTF-KD will have sensitivity to some chemotherapies.
• Aim 2: To investigate the role of autophagy in the sensitization of BPTF-KD
cells to chemotherapies. It is expected that BPTF-KD cells will have an
enhanced sensitivity to Doxorubicin through the blockade of autophagy by ATG5
KD. 4T1 TNBC cells with BPTF and ATG5-KD will be transplanted into mice and
tumor weight will be measured to see the response of the cells to chemotherapy
after autophagy inhibition in vivo.
• Aim 3: Determine the possible molecular consequences of treating BPTF-KD
cells with chemotherapies. Natural Killer (NK) cells will be depleted in mice to
investigate role in sensitization to therapies.
Ultimately this thesis’ goal is to develop strategies combining NURF
targeted therapies with breast cancer chemotherapies to improve clinical
outcomes.
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Figure1 shows BPTF-KD
(KD1 and KD2) in the 4T1
mouse TNBC cell line. It
also shows no reductions in
any of the other subunits.
Cyclophilin B is used as
loading control.

Figure 7
Figure 7 shows results from syngeneic mouse
models. It shows sensitization to Doxorubicin
in BPTF-KD cells, but no sensitization in
BPTF-WT cells that were ATG5-KD.

Figure 3
Figure 3 Acridine Orange
staining shows enhanced
autophagy in cells treated with
chemotherapies in comparison to
controls.

Figure 1

Figure 2 shows sensitization to different types
of chemotherapies in the WT, KD1 and KD2
cell lines. The highest sensitization can be
seen in Doxorubicin as it has the smallest
number of viable cells in KD1 and KD2 cell
lines.
Figure 2

Figure 8
Figure 8 shows that when
we KD Natural Killer (NK)
cells in mice they lose that
initially seen sensitization to
Doxorubicin.

Figure 10
Figure 11
Figure 10 shows a visible
Figure 11 shows increase in
reduction in PGE2 when
COX 1 and COX 2
autophagy was blocked in the expression in Doxorubicin
BPTF-KD cells.
treated cell lines. COX 2
expression is higher in
ATG5-KD cells.
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Methodology
• Short hairpin RNA was used for BPTF and ATG5-KD which was confirmed
through Western Blot.
• Clonogenic survival assays were used to see the effects chemotherapies on the
BPTF-KD cells as well to investigate the roll of autophagy in plated cells.
• Acridine staining was used to test for enhanced levels of autophagy in BPTF-KD
cells
• Clonogenic survival assays were used to measure toxicity of chemotherapies to
BPTF-KD cells.
• Blockade of autophagy after ATG5-KD was measured by LC3B-I conversion to
LC3B-II.
• Syngeneic mouse models were used to determine sensitization to Doxorubicin
with BPTF-KD as well as with ATG5-KD in vivo.
• Mass spectrometry was used to measure eicosanoid abundance in culture media.
• Reverse ELISA was used to analyze PGE2 concentration in all the cell lines.
• rt-PCR was used to analyze cytokine gene expression data.

Figure 9
Figure 9 reductions in PGE2 (known
NK cell inhibitor) seen in BPTF-KD
cells treated with chemotherapy
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Figure 4
Figure 4 shows ATG5-KD.
Cyclophilin B is shown as the loading
control and BPTF-KD is also shown
for KD1 and KD2 cell lines.

KD1

KD2

Figure 5
Figure 5 shows functional blockade
of autophagy through LC3B-I
conversion to LC3B-II. GAPDH is
used as loading control.

Figure 6 clonogenic survival assays suggest
that autophagy is cytoprotective in WT cells
and nonprotective in BPTF-KD cells.
Figure 6

• Aim 1 results: Sensitivity is enhanced to select chemotherapies when NURF is
depleted with BPFT-KD. Results also show enhanced autophagy in BPTF-KD cells treated
with Doxorubicin. Doxorubicin had the lowest amount of viable cells.
• Aim 2 results: ATG5 KD increased sensitization to Doxorubicin in BPTF-WT cells but
not BPTF-KD cells. This suggests that the autophagy is cytoprotective in the WT cells
and nonproductive in the BPTF KD cells. BPTF-KD cell lines (KD1 & KD2) showed
sensitization to Doxorubicin in syngeneic mouse models. Mouse models also showed
sensitization in ATG5-KD cell lines with BPTF-WT but not the cell lines with BPTF-KD.
• Aim 3 results show that when Natural Killer cells are depleted in mice, the initial
sensitization is lost. This could be explained by cytokine or metabolite secretion to the
tumors or by altered gene expression. The metabolomics screen showed reductions in
PGE2 in the BPTF-KD cells treated with chemotherapies. This explains improvements in
tumor growth seen in the mice since PGE2 is a known NK cell inhibitor. rt-PCR analysis of
cytokine gene expression in the BPTF-KD and the ATG5-KD cells showed no significant
expression in any of the cytokines within the cell lines. The PGST1 and PGST2 gene
expression data suggests that COX 2 is regulated by autophagy and autophagy is important
for PGE2 secretion with or without Doxorubicin.
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